Low Omicron BA.4 and BA.5 neutralising activity and breakthrough COVID-19 following pre-exposure prophylaxis with tixagevimab plus cilgavimab in vaccinated patients with autoimmune disease.

导出 LinkOut

翻译打印收藏纠错

作者： Caoilfhionn M,Connolly ^[1] ; Andrew H,Karaba ^[2] ; Teresa,Po-Yu Chiang ^[3] ; Mayan,Teles ^[3] ; Jake D,Kim ^[3] ; Trevor,Scott Johnson ^[2] ; Jennifer L,Alejo ^[3] ; Dorry L,Segev ^[4] ; Lisa,Christopher-Stine ^[1] ; William A,Werbel ^[2] ; Julie J,Paik ^[5]

作者单位： Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ^[1] Division of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ^[2] Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, MD, USA. ^[3] Department of Surgery, NYU Grossman School of Medicine, New York, NY, USA. ^[4] Division of Rheumatology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. jpaik1@jhmi.edu. ^[5]

主题词人类(Humans);自身免疫疾病(Autoimmune Diseases);抗体, 病毒(Antibodies, Viral)

DOI 10.55563/clinexprheumatol/pfli7o

PMID 36826787

发布时间 2024-01-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交